Milašinović, B.; Marković, S.; Vezmar Kovačević, S.; Svorcan, P.; Miljković, B.; Vučićević, K.
Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment. Pharmaceuticals 2026, 19, 1239.
https://doi.org/10.3390/ph19081239
AMA Style
Milašinović B, Marković S, Vezmar Kovačević S, Svorcan P, Miljković B, Vučićević K.
Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment. Pharmaceuticals. 2026; 19(8):1239.
https://doi.org/10.3390/ph19081239
Chicago/Turabian Style
Milašinović, Bojana, Srđan Marković, Sandra Vezmar Kovačević, Petar Svorcan, Branislava Miljković, and Katarina Vučićević.
2026. "Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment" Pharmaceuticals 19, no. 8: 1239.
https://doi.org/10.3390/ph19081239
APA Style
Milašinović, B., Marković, S., Vezmar Kovačević, S., Svorcan, P., Miljković, B., & Vučićević, K.
(2026). Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment. Pharmaceuticals, 19(8), 1239.
https://doi.org/10.3390/ph19081239